INT207830

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.65
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 10
Total Number 10
Disease Relevance 0.49
Pain Relevance 1.97

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (GAD2) lyase activity (GAD2) Golgi apparatus (GAD2)
cytoplasmic membrane-bounded vesicle (GAD2) plasma membrane (GAD2) cytoplasm (GAD2)
Anatomy Link Frequency
Islets of Langerhans 1
cell body 1
GAD2 (Homo sapiens)
Pain Link Frequency Relevance Heat
tetrodotoxin 90 99.10 Very High Very High Very High
antagonist 72 98.70 Very High Very High Very High
gABA 81 98.68 Very High Very High Very High
Somatostatin 27 97.52 Very High Very High Very High
Cannabinoid receptor 14 92.84 High High
GABAergic 69 80.20 Quite High
Action potential 72 67.76 Quite High
fluoxetine 2 62.44 Quite High
conotoxin 108 49.52 Quite Low
addiction 27 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hyperinsulinism 9 99.16 Very High Very High Very High
Generalized Anxiety Disorder 1 91.76 High High
Hypoglycemia 18 86.68 High High
Amblyopia 7 79.60 Quite High
Aging 17 38.56 Quite Low
Diabetes Mellitus 63 19.64 Low Low
Lifespan 27 5.00 Very Low Very Low Very Low
Impaired Glucose Tolerance 18 5.00 Very Low Very Low Very Low
Cataract 1 5.00 Very Low Very Low Very Low
Anxiety Disorder 1 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
GAD65 is localized in the axon terminals and synthesizes the on-demand pool of GABA, while GAD67 is located in the cell body and synthesizes the basal pool of GABA (Feldblum et al., 1993, 1995).
Localization (localized) of GAD65 in cell body associated with gaba
1) Confidence 0.65 Published 2010 Journal Frontiers in Cellular Neuroscience Section Body Doc Link PMC2893712 Disease Relevance 0.24 Pain Relevance 0.52
Cells Regulates Glucagon Release from Both Rodent and Human Islets of Langerhans

Glucagon, secreted from pancreatic islet ?

Localization (secreted) of Islets in Islets of Langerhans
2) Confidence 0.01 Published 2007 Journal PLoS Biology Section Title Doc Link PMC1868042 Disease Relevance 0 Pain Relevance 0.04
We show that glucose retained the ability to suppress glucagon release from isolated islets during blockade of the Zn2+ and GABA paracrine pathways, and in the absence of stimulated insulin secretion or ?
Localization (release) of islets associated with gaba
3) Confidence 0.01 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0.09 Pain Relevance 0.15
It is worth noting that in the presence of the GABAA antagonist, glucagon secretion was increased under both low- and high-glucose conditions, and furthermore, glucose was approximately 50% less effective in suppressing glucagon release from mouse islets (31% versus 60%, respectively) (Figure 1A).
Localization (release) of islets associated with antagonist
4) Confidence 0.01 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0 Pain Relevance 0.28
It is notable that the increase in glucagon release from the Kir6.2Y12X islets was coincident with increased insulin secretion, reinforcing the view that inhibition of glucagon is not mediated by a factor released by the ?
Localization (release) of islets associated with hyperinsulinism
5) Confidence 0.01 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0.10 Pain Relevance 0
However, the somatostatin receptor 2 (SSTR-2) antagonist PRL-2903 does not interfere with the ability of glucose (at 3 and 7 mM) to inhibit glucagon secretion from mouse islets [47].
Localization (secretion) of islets associated with antagonist and somatostatin
6) Confidence 0.01 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0 Pain Relevance 0.26
TTX has no effect on glucose-stimulated insulin secretion in mouse islets (Figure 7A); again suggestive of a direct rather than indirect effect on ?
Localization (secretion) of islets associated with tetrodotoxin
7) Confidence 0.01 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0 Pain Relevance 0.65
The GABAA receptor antagonist SR95531 had no effect on glucose-induced inhibition of glucagon secretion from human islets, and whole-cell voltage-clamp measurements indicate that human ?
Localization (secretion) of islets associated with antagonist
8) Confidence 0.01 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0 Pain Relevance 0.05
M inhibited glucagon secretion in parallel with an inhibition of insulin release from both mouse and rat islets (Figure 2A and 2B).
Localization (release) of islets
9) Confidence 0.01 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0 Pain Relevance 0.03
In wild-type islets, glucagon secretion exhibited a nadir at 5 mM glucose, and glucagon secretion at 20 mM glucose was 40% higher than at 5 mM glucose.
Localization (secretion) of islets
10) Confidence 0.01 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0.07 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox